Potential Alzheimer’s Treatment, Now in Phase 3 Testing, Gets Boost from FDA

Potential Alzheimer’s Treatment, Now in Phase 3 Testing, Gets Boost from FDA
Aducanumab, an amyloid-fighting medication being developed by Biogen for Alzheimer's disease (AD), has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The treatment is currently being evaluated in two large-scale Phase 3 trials, both of which are recruiting Alzheimer's patients. The FDA’s fast track program allows for faster approval of medications for serious conditions that are not adequately treated, such as AD. “By collaborating with regulators through programs like Fast Track, we hope to bring effective treatments to patients and families affected by Alzheimer’s disease as quickly as possible,” Alfred Sandrock, MD, PhD, executive vice president and chief medical officer at Biogen, said 
Subscribe or to access all post and page content.